Matrix Pharma other research news

MATX (Menlo Park, Calif.) presented animal research on its drug delivery technology, showing enhanced local delivery of anti-cancer agents with limited systemic toxicities.

The IntraDose-FU injectable gel form of fluorouracil was studied in a mouse fibrosarcoma model. Tumors injected with the agent showed a 65-fold higher concentration of drug after an hour compared to direct injection of fluorouracil. Moreover, lower concentrations were seen in the kidneys and liver. ...